Cargando…

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension (PH) is defined as a disorder in which the mean Pulmonary Arterial Pressure (mPAP) is greater than 20 mmHg at rest. Pulmonary Arterial Hypertension (PAH) is considered when mPAP is > 20 mmHg and pulmonary vascular resistance (PVR) is ⩾ 3 WU. PAH is a chronic progressive dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohammadi, Asma, Matos, Wanessa F, Intriago, Cesar, Thakkar, Keval, Jahan, Nasrin, Shah, Heeya, Nishu, Rifath I, Marzban, Sima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533662/ https://www.ncbi.nlm.nih.gov/pubmed/34707962 http://dx.doi.org/10.7759/cureus.18191

Ejemplares similares

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

598. Clinical Characteristics and Characterization of Hafnia Alvei Infections in Cancer Patients
por: Thakkar, Keval, et al.
Publicado: (2023)

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Lambert, Olivier, et al.
Publicado: (2012)

Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
por: Chebib, Nader, et al.
Publicado: (2017)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

A Case of Chronic Pulmonary Embolism Resulting in Pulmonary Hypertension and Decompensated Right Heart Failure
por: Hosna, Asma U, et al.
Publicado: (2022)

Severe Pulmonary Artery Hypertension in Otherwise Silent Lupus: A Unique Hybrid Treatment Approach Using Hydroxychloroquine and Sildenafil
por: Saleem, Maleeha, et al.
Publicado: (2022)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Post-COVID-19 Pulmonary Fibrosis
por: Mohammadi, Asma, et al.
Publicado: (2022)

Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy
por: Javed, Aneeqa, et al.
Publicado: (2022)

Complex transposition of the great arteries with pulmonary arterial hypertension and giant pulmonary artery aneurysm
por: Leong, Kai’En, et al.
Publicado: (2018)

An unusual case of pulmonary arterial hypertension
por: Bulnes, Juan F, et al.
Publicado: (2021)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report
por: Mohan, Nishtha, et al.
Publicado: (2022)

Features of Kidney Function in Patients With Comorbidity of Arterial Hypertension and Chronic Obstructive Pulmonary Disease
por: Boiko, Olha, et al.
Publicado: (2022)

Obstructive Sleep Apnea and Pulmonary Hypertension: A Review of Literature
por: Shah, Farhan A, et al.
Publicado: (2021)

Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data
por: Ingram, Dominique, et al.
Publicado: (2022)

Reversed Potts Shunt Outcome in Suprasystemic Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Mendel, Brian, et al.
Publicado: (2022)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Evaluation of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
por: Aurangabadkar, Gaurang M, et al.
Publicado: (2022)

A rare case of unilateral agenesis of left pulmonary artery presenting as severe pulmonary arterial hypertension
por: Malani, Susheel Kumar, et al.
Publicado: (2023)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Multifactorial Pulmonary Hypertension in Systemic Sclerosis
por: Hussain, Habiba, et al.
Publicado: (2020)

Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
por: Kuzuya, Kentaro, et al.
Publicado: (2019)

Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review
por: Nahar, Shamsun, et al.
Publicado: (2023)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Infantile Scimitar Syndrome With Contralateral Pulmonary Vein Stenosis and Refractory Pulmonary Hypertension
por: Buysse, Janelle, et al.
Publicado: (2021)

Cardiac Papillary Fibroelastoma: Pulmonic Valve Involvement With Pulmonary Embolism and Pulmonary Hypertension
por: Jilani, Danish, et al.
Publicado: (2022)

Severe arterial pulmonary hypertension in a 34-year-old patient
por: Rueda, Darío A., et al.
Publicado: (2022)

Mycophenolate Mofetil in a Lupus Patient with Pulmonary Hypertension
por: Machireddy, Kirthi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ps175p3fu7820c2nga765sskpi